Associated Papers
Potential Opportunities for Pharmacogenetic-Based Therapeutic Exploitation of Xanthine Dehydrogenase in Cardiovascular Disease.
Massimo G et al.
Antioxidants (basel, Switzerland), 2024
An ancestral variant causing type I xanthinuria in Turkmen and Arab families is predicted to prevail in the Afro-Asian stone-forming belt.
Peretz H et al.
Jimd Reports, 2020
Identification of a xanthinuria type I case with mutations of xanthine dehydrogenase in an Afghan child.
Nakamura M et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.
Ichida K et al.
International Journal of Molecular Sciences, 2012
Novel mutations in xanthine dehydrogenase/oxidase cause severe hypouricemia: biochemical and molecular genetic analysis in two Czech families with xanthinuria type I.
Stiburkova B et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
Xanthine dehydrogenase deficiency with novel sequence variations presenting as rheumatoid arthritis in a 78-year-old patient.
Jurecka A et al.
Journal of Inherited Metabolic Disease, 2010
Functional characterization of human xanthine oxidase allelic variants.
Kudo M et al.
Pharmacogenetics and Genomics, 2008
Xanthinuria type I: a rare cause of urolithiasis.
Arikyants N et al.
Pediatric Nephrology (berlin, Germany), 2007
Select a paper to view details